Real-World Evidence of the Cambridge Hybrid Closed-Loop App With a Novel Real-Time Continuous Glucose Monitoring System-Reference-Cited by-同舟云学术

Real-World Evidence of the Cambridge Hybrid Closed-Loop App With a Novel Real-Time Continuous Glucose Monitoring System

Published:2023-07-28 Issue: Volume: Page:
ISSN:1932-2968
Container-title:Journal of Diabetes Science and Technology
language:en
Short-container-title:J Diabetes Sci Technol

Author:

Newman Christine¹^ORCID,Hartnell Sara¹,Wilinska Malgorzata²³,Alwan Heba²⁴,Hovorka Roman²³^ORCID

Affiliation:

1. Wolfson Diabetes and Endocrinology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

2. Wellcome-MRC Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK

3. Department of Paediatrics, University of Cambridge, Cambridge, UK

4. Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland

Abstract

We evaluated the performance of the interoperable Cambridge hybrid closed-loop app with FreeStyle Libre 3 glucose sensor, and YpsoPump insulin pump in a real-world setting. Data from 100 users (63 adults [mean ± SD age 41.9 ± 14.0 years], 15 children [8.6 ± 5.2 years)] and 22 users of unreported age) for a period of 28 days were analyzed. Time in range (3.91- 10.0mmol/L) was 72.6 ± 11.1% overall. Time below range (<3.9mmol/L) was 3.1% (1.4-5.1) (median [interquartile range]). Auto-mode was active for 95.8% (91.8-97.9) of time. This real-world analysis suggests that the performance of Cambridge hybrid closed-loop app with this glucose sensor is comparable to other commercially available hybrid closed-loop systems.

Publisher

SAGE Publications

Subject

Biomedical Engineering,Bioengineering,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/19322968231187915

Reference19 articles.

1. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice

2. The Artificial Pancreas and Type 1 Diabetes

3. Abbott’s FreeStyle® Libre 3 system receives CE mark*: features world’s smallest, thinnest sensor with best-in-class performance at the same low cost for people with diabetes. https://www.abbott.co.uk/media-center/news/abbotts-freestyle-libre-3-system-receives-ce-mark.html. Accessed July 10, 2023.